Should I get a ngs test for panc cancer

May 16, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

NGS Testing for Pancreatic Cancer: What You Should Know

That's a great question. Let me explain the clinical thinking around NGS (Next-Generation Sequencing) testing for pancreatic cancer, then help you prepare questions for your oncologist.

Why NGS Matters for Pancreatic Cancer

The Clinical Framework: Pancreatic cancer is one of the most aggressive cancers, and standard chemotherapy alone has limited effectiveness. However, recent advances have shown that genetic mutations in pancreatic tumors can open up targeted treatment options — but only if you know what mutations are present. That's where NGS comes in.

NGS testing sequences your tumor's DNA to identify specific mutations that might respond to:

  • Targeted therapies (drugs designed to attack specific mutations)
  • Immunotherapies (drugs that help your immune system fight cancer)
  • Clinical trials (newer treatments not yet widely available)

What NCCN Guidelines Recommend

According to NCCN Guidelines for Pancreatic Adenocarcinoma, genetic/genomic testing is recommended for:

  • Patients with metastatic (advanced) pancreatic cancer
  • Patients being considered for clinical trials
  • Those with specific family histories of cancer
  • Anyone exploring treatment options beyond standard chemotherapy

The American Cancer Society also emphasizes that tumor genetic testing can help identify patients who may benefit from precision medicine approaches.

Key Mutations That Change Treatment

Some mutations found in pancreatic cancer include:

  • BRCA1/BRCA2 mutations — may respond to platinum-based chemotherapy or PARP inhibitors
  • Mismatch repair (MMR) deficiency — may respond to immunotherapy
  • KRAS mutations — emerging targeted therapies becoming available
  • Other actionable mutations — may open clinical trial options

Questions to Ask Your Oncologist

Before deciding on NGS testing, ask your doctor:

  1. "Do you recommend NGS testing for my specific stage and type of pancreatic cancer?"
  2. "What mutations, if found, would change my treatment plan?"
  3. "Will the results help me access clinical trials or targeted therapies?"
  4. "How long does testing take, and will it delay my treatment?"
  5. "Does my insurance cover NGS testing, and what are the out-of-pocket costs?"

Important Context

  • Timing matters: NGS results typically take 1-2 weeks, so discuss whether testing delays your treatment start
  • Tissue requirements: Your doctor needs adequate tumor tissue (usually from your biopsy or surgery)
  • Not all mutations have treatments yet: Some findings may not immediately change your care, but they inform your medical team and may open future options

Bottom Line

For most pancreatic cancer patients, especially those with advanced disease, NGS testing is increasingly standard practice because it can identify treatment options that wouldn't otherwise be considered. However, whether it's right for you depends on your specific situation, stage, and treatment goals.

Your oncologist is best positioned to determine if NGS testing makes sense for your case and timeline.


This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...

TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2